TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06188572

Intervention type: OTHER
Intervention: Michigan Neuropathy Screening Instrument
Description: A two-step test consisting of symptom questionnaire and physical examination was used. The symptom questionnaire includes 15 questions about the legs and feet. Physical examination includes assessment of the appearance of the feet, Achilles reflex, thumb vibration and monofilament tests.

Intervention type: OTHER
Intervention: Michigan Neuropathy Screening Instrument
Description: A two-step test consisting of symptom questionnaire and physical examination was used. The symptom questionnaire includes 15 questions about the legs and feet. Physical examination includes assessment of the appearance of the feet, Achilles reflex, thumb vibration and monofilament tests.

Intervention type: OTHER
Intervention: Numeric Pain Scale
Description: In this simple method, which is frequently used to measure pain intensity in the clinic and whose validity and reliability have been demonstrated, the participant is asked to mark a number on a 10 cm scale with numbers ranging from 0 (no pain) to 10 (unbearable pain) for the pain.

Intervention type: OTHER
Intervention: Numeric Pain Scale
Description: In this simple method, which is frequently used to measure pain intensity in the clinic and whose validity and reliability have been demonstrated, the participant is asked to mark a number on a 10 cm scale with numbers ranging from 0 (no pain) to 10 (unbearable pain) for the pain.

Intervention type: OTHER
Intervention: Mandibular Function Disorder Questionnaire
Description: This valid and reliable scale evaluating mandibular dysfunction consists of two dimensions and 17 questions.A high total score obtained from the questionnaire indicates a high level of impairment in jaw function

Intervention type: OTHER
Intervention: Mandibular Function Disorder Questionnaire
Description: This valid and reliable scale evaluating mandibular dysfunction consists of two dimensions and 17 questions.A high total score obtained from the questionnaire indicates a high level of impairment in jaw function

Intervention type: OTHER
Intervention: Fonseca Anamnestic Index
Description: This scale, which is valid and reliable as a TMJ disorder assessment tool, includes 10 questions. The presence of TMD is accepted in those with a score of 25.

Intervention type: OTHER
Intervention: Fonseca Anamnestic Index
Description: This scale, which is valid and reliable as a TMJ disorder assessment tool, includes 10 questions. The presence of TMD is accepted in those with a score of 25.

Intervention type: OTHER
Intervention: Ferrans&Powers Quality of Life Index Diabetes Version
Description: This index consists of two parts and a total of 68 items. A high score indicates a good quality of life.

Intervention type: OTHER
Intervention: Ferrans&Powers Quality of Life Index Diabetes Version
Description: This index consists of two parts and a total of 68 items. A high score indicates a good quality of life.
Study: NCT05534347

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Addtional tube of blood needed for follow up of patients

Intervention type: BIOLOGICAL
Intervention: Joint puncture
Description: Joint puncture if needed according to routine care of the patients
Study: NCT05641558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611 150mg
Description: subcutaneous injection, 150 mg (single dose treatment period) + 300mg (loading dose, week 0) + 150mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611 300mg
Description: subcutaneous injection, 300 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 1 to Week 15, 8 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611 600mg
Description: subcutaneous injection, 600 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: During the study, placebos shall be filled timely according to the administration of the test drug to ensure the consistency of the times of administration in each group, so as to maintain the blind state.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: During the study, placebos shall be filled timely according to the administration of the test drug to ensure the consistency of the times of administration in each group, so as to maintain the blind state.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: During the study, placebos shall be filled timely according to the administration of the test drug to ensure the consistency of the times of administration in each group, so as to maintain the blind state.
Study: NCT04945720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion chemotherapy（HAIC）
Description: hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients received anti-PD-L1 agents will begin no earlier than 7 days following the first HAIC procedure. Anti-PD-L1 agents were used intravenously at the standard dose: Durvalumab was given every 3 weeks during HAIC treatment (Q3W) and every 4 weeks after HAIC treatment (Q4W).
Study: NCT04677972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ebselen
Description: Glutathione peroxidase mimetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo containing excipients
Study: NCT06359210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responder Monthly Behavior Change Discussion Sessions
Description: Monthly behavior change discussion sessions (3 total) for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incomplete Responder Monthly Behavior Change Discussion Sessions
Description: Monthly behavior change discussion sessions (3 total) for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incomplete Responder Monthly Behavior Change Discussion Sessions + Bi-Weekly Exercise Sessions
Description: Monthly behavior change discussion sessions (3 total) for 12 weeks and attend bi-weekly (every other week) exercise classes that mirror the exercises completed in their respective community-based exercise program.
Study: NCT04496180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed incision negative pressure therapy versus standard dressing after emergency abdominal laparotomies
Description: Target population is every patient undergoing a laparotomic procedure and responding to inclusion criteria marked in paragraph 3.8 (see forward) A member of the medical surgery team should apply the PREVENA just after the surgical procedure.~A medical member (nurse specialist in wound care) of the surgical team removes the dressing. All other manipulations of the therapy unit, the connector and the cartridge can be carried out by any nurse practitioner in hospital or extra hospital environment but must warn the investigators.~The aspiration will be stopped 24 hours before and the dressing is removed by a nurse at home or in the hospital.~The specialized nurse who will take a photo and assess the condition of the wound in the treatment room.~One of the investigators, non-operators, who will also assess the condition of the wound by photo.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed incision negative pressure therapy versus standard dressing after emergency abdominal laparotomies
Description: Target population is every patient undergoing a laparotomic procedure and responding to inclusion criteria marked in paragraph 3.8 (see forward) A member of the medical surgery team should apply the PREVENA just after the surgical procedure.~A medical member (nurse specialist in wound care) of the surgical team removes the dressing. All other manipulations of the therapy unit, the connector and the cartridge can be carried out by any nurse practitioner in hospital or extra hospital environment but must warn the investigators.~The aspiration will be stopped 24 hours before and the dressing is removed by a nurse at home or in the hospital.~The specialized nurse who will take a photo and assess the condition of the wound in the treatment room.~One of the investigators, non-operators, who will also assess the condition of the wound by photo.
Study: NCT06162767

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy by Ivor-Lewis Procedure
Description: Esophagectomy was conducted by Ivor-Lewis Procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy by Optimized Sweet Procedure
Description: Esophagectomy was conducted by Optimized Sweet Procedure.
Study: NCT04866550

Intervention type: OTHER
Intervention: Data collection
Description: Daily record of temperature, weight, heart rate, systolic blood pressure and oxygen saturation
Study: NCT04721457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: Control group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Povidone Iodine (PVP-I)
Description: Over-the-counter antiseptic mouth rinse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5% Hydrogen Peroxide (H2O2)
Description: Over-the-counter antiseptic mouth rinse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.075% Cetylpyridinium Chloride (CPC)
Description: Over-the-counter antiseptic mouth rinse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Sodium Hypochlorite
Description: Over-the-counter antiseptic mouth rinse

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No rinse group
Description: second control group
Study: NCT05731713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Journey of Transformation-Native Youth Health Leadership Program curriculum
Description: Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Journey of Transformation-Native Youth Health Leadership Program curriculum
Description: Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
Study: NCT06106503

Intervention type: RADIATION
Group type: OTHER
Intervention: chest x-ray
Description: chest x-ray after rigid bronchoscopy for patient with foreign body inhalation

Intervention type: OTHER
Group type: OTHER
Intervention: clinical examination
Description: no investigations well be done unless needed
Study: NCT06546579

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skin sampling
Description: All individuals will self-collect skin samples and swabs and fill in a questionnaire. Subsequently, all individuals will see a professional. The professional will collect skin samples and swabs as well.
Study: NCT05362877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Applying exercise to reduce the symptoms of temporomandibular disorder
Study: NCT05864625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: During induction, patients allocated to the remimazolam group will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combied with remifetanil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol/ Sevoflurane
Description: During induction, patients allocated to the P/S group will receive propofol 1% 1-2mg/kg with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with sevoflurane and remifentanil.
Study: NCT04931927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Connections Intervention-Telehealth (MCI-T)
Description: Single session telehealth engagement intervention plus telehealth treatment as usual (TAU) \[MCI-T +TAU\]

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Telehealth treatment as usual without the single session telehealth engagement intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Telehealth treatment as usual without the single session telehealth engagement intervention
Study: NCT04955912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music medicine
Description: To reduce premenstrual symptoms by applying music medicine to people with premenstrual syndrome
Study: NCT06124209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TachoSil
Description: TachoSil used in Vena Cava Inferior anastomosis during liver transplantation.
Study: NCT04639128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Catheter
Description: The adductor canal catheter is a medical device that consists of a tunneled catheter connected to an analgesic solution-containing reservoir that slowly infuses the anesthetic over the first 2-3 postoperative days
Study: NCT04685759

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Exercise Protocol
Description: Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes per in-person session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Exercise Protocol
Description: Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes each virtual session. A TheraBand (resistance band) will be provided to patients in this group to be used for resistance and flexibility training.
Study: NCT05216614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine is an SSRI used for depression and anxiety disorders. This study will investigate the efficacy of fluvoxamine for improvement of olfactory dysfunction in subjects with post-Covid-19 parosmia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose placebo capsules identical to fluvoxamine capsules in order to preserve blind
Study: NCT05455242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit formation
Description: Habit formation interventions to promote context-dependent automatic behaviors to support diabetes self-management.
Study: NCT05851235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation course
Description: During prehabilitation course, patients will follow a nutritional programme, a cardiovascular and motor programme and a psychological programme.
Study: NCT05791136

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 95% PGTV56-60Gy/28-30 fractions, 2Gy/1 fractions; 95% PTV50.4-54Gy/28-30 fractions, 1.8Gy/1 fractions; 5 days a week; 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab (200 mg, intravenously infused) will be administered as the maintenance treatment every 3 weeks within 4 weeks after the completion of radiotherapy for 1 years or until progression, intolerable toxicity, or physician/patient decision
Study: NCT06015373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: supress the night dose of carvedilol
Description: already described
Study: NCT05955703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ppm based training
Description: The training program based on the precede proceed model was applied to hemodialysis patients for 8 sessions. Eight sessions of training were given to the experimental group within the scope of the model, a booklet was developed in line with the trainings and posters were prepared.
Study: NCT06352008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg once a day, taken orally before breakfast for 2 consecutive weeks and stopped for 1 week. Without special circumstances, it is recommended to take at a fixed time every day; If there is a missing dose during the administration, confirm that the time before the next administration is less than 12 hours, no more refilling. The maximum duration of drug use is tentatively 1 year.
Study: NCT06025474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20Mg Tab
Description: Encapsulated vortioxetine immediate release tablets, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine 20 Mg Oral Tablet
Description: Encapsulated paroxetine tablets, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline 50 MG
Description: Encapsulated sertraline tablets, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram 20mg
Description: Encapsulated citalopram tablets, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram 10mg
Description: Encapsulated escitalopram tablets, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 60 MG
Description: Encapsulated duloxetine tablets, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg
Description: Encapsulated pregabalin tablets, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg
Description: Encapsulated pregabalin tablets, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg
Description: Encapsulated pregabalin tablets, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg
Description: Encapsulated pregabalin tablets, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg
Description: Encapsulated pregabalin tablets, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: Encapsulated pregabalin tablets, once daily
Study: NCT05562882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Injection
Description: intravenous daratumumab administration
Study: NCT05612074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Inhaled nitric oxide (Medical grade, in NO/N2 tanks) will be delivered in a oxygen-air-nitrogen mixture for 30 minutes three times per day
Study: NCT05257772

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV Delay Optimised RV Pacing
Description: AV Delay Optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems) and Echo to assess LVOT gradient change.
Study: NCT06087341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NKG2D-CAR memory T cell
Description: Patients will be allocated in two groups: Arm A and Arm B. Both groups will receive an intravenous infusion of NKG2D-CAR memory T cells. Additionally, patients on Arm B will receive an intratumoral dose of NKG2D-CAR memory T cells (in accessible primary tumor and metastases). The distribution of patients on one arm or other will depend on their clinical characteristics described in the inclusion/ exclusion criteria. All patients will receive lymphodepleting chemotherapy prior to the infusion of NKG2D-CAR memory T cells according to the usual clinical practice in our center. Some patients will also receive low dose radiotherapy prior to infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NKG2D-CAR memory T cell
Description: Patients will be allocated in two groups: Arm A and Arm B. Both groups will receive an intravenous infusion of NKG2D-CAR memory T cells. Additionally, patients on Arm B will receive an intratumoral dose of NKG2D-CAR memory T cells (in accessible primary tumor and metastases). The distribution of patients on one arm or other will depend on their clinical characteristics described in the inclusion/ exclusion criteria. All patients will receive lymphodepleting chemotherapy prior to the infusion of NKG2D-CAR memory T cells according to the usual clinical practice in our center. Some patients will also receive low dose radiotherapy prior to infusion.
Study: NCT05019092

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound examination of lower limb veins
Description: Ultrasound examination will be performed by trained physicians using a commercially available ultrasound system and 5.0-15.0 MHz linear probe. The examinations consists of a comprehensive B-mode ultrasound protocol, from thigh to ankle, employing compression and color-Doppler at selected sites, according to the Consensus Conference of the Society of Radiologists in Ultrasound.
Study: NCT06265545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib,Venetoclax,gilteritinib,Selinexor
Description: if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib,Venetoclax,gilteritinib,Selinexor
Description: if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib,Venetoclax,gilteritinib,Selinexor
Description: if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib,Venetoclax,gilteritinib,Selinexor
Description: if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib,Venetoclax,gilteritinib,Selinexor
Description: if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib,Venetoclax,gilteritinib,Selinexor
Description: if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib,Venetoclax,gilteritinib,Selinexor
Description: if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)